Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03792633 · ClinicalTrials.gov registry record · Phase 2
Study of huCART19 for Very High-Risk (VHR) Subsets of Pediatric B-ALL
A Phase 2 study, sponsored by University of Pennsylvania.
- Completed
- Registry status
- Phase 2
- Development phase
- 106
- Enrollment target
NCT03792633: Completed Phase 2 study, sponsored by University of Pennsylvania.
NCT03792633 is a Phase 2 study that has completed, run by University of Pennsylvania. The registered enrollment target is 106 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03792633, a Phase 2 study, has completed, sponsored by University of Pennsylvania.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 106 participants
- Enrollment target
Study Summary
This is a phase 2 study to evaluate humanized CD19 redirected autologous T cells (or huCART19 cells) with CD19 expressing relapsed and refractory B-cell acute lymphoblastic leukemia. This study is targeting pediatric and young adult patients aged 3 months - 29 years with CD19+ B cell malignancies in newly diagnosed B-ALL patients predicted to have an exceedingly poor outcome with conventional chemotherapy, in high-risk first relapse, or and in second or greater relapse in this phase 2 trial. In addition, a second cohort will test the efficacy of huCART19 in patients with poor response to prior B cell directed engineered cell therapy.
Interventions
- BIOLOGICAL huCART19
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 106 participants |
| Start Date | 2019-01-18 |
| Est. Completion | 2024-04-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03792633
The ClinicalTrials.gov registry entry for NCT03792633 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 106 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Pennsylvania, which has 1,423 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which huCART19 is the first listed.
NCT03792633 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03792633 about?
NCT03792633 is a clinical study titled "Study of huCART19 for Very High-Risk (VHR) Subsets of Pediatric B-ALL". This is a phase 2 study to evaluate humanized CD19 redirected autologous T cells (or huCART19 cells) with CD19 expressing relapsed and refractory B-cell acute lymphoblastic leukemia. This study is targeting pediatric and young adult patients aged 3 months - 29 years with CD19+ B cell malignancies in...
What is the current status of trial NCT03792633?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 106 participants. The study started on 2019-01-18. Estimated completion is 2024-04-04.
What interventions are being tested in trial NCT03792633?
The interventions under investigation include: huCART19 (BIOLOGICAL).
Who is sponsoring clinical trial NCT03792633?
This trial is sponsored by University of Pennsylvania, which has 1,423 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.